Table 1.
Comparison of baseline characteristics between control and the patient group.
| Controls (n = 49) | Patients (n = 67) | T-Test | |
|---|---|---|---|
| Age (years) | 62 ± 11 | 65 ± 13 | ns |
| Female/male | 15/34 | 18/49 | ns |
| Mean blood pressure (mm Hg) | 87 ± 17 | 89 ± 15 | ns |
| Systolic blood pressure (mmHg) | 115 ± 16 | 118 ± 21 | ns |
| Diastolic blood pressure (mmHg) | 64 ± 16 | 63 ± 17 | ns |
| Mean Blood pressure variability (mm Hg) |
L, 17 ± 4 R, 16 ± 3 |
L, 19 ± 5 R, 19 ± 5 |
L, df 115, t = −2.38, p < 0.05,d = 0.44 R, df 113, t = −2.88, p < 0.005, d = 0.72 |
| Heart rate (beats/min) | 68 ± 9 |
lL, 66 ± 10 R, 66 ± 11 |
ns ns |
| ETCO2 (mm Hg) | 40 ± 3.9 | 39 ± 5.0 | ns |
| Cerebral blood flow velocity (cm/s) |
L, 45 ± 10 R, 57 ± 13 |
L, 53 ± 13 R, 52 ± 12 |
L, ns R, ns |
| Cerebrovascular resistance (mm Hg / cm/s) |
L, 1.43 ± 0.43 R, 1.46 ± 0.41 |
L, 1.75 ± 0.52 R, 1.77 ± 0.44 |
L, df 115, t = −1.95, p = 0.05, d = 0.67 R, df 113, t = −3.66, p < 0.005, d = 0.72 |
| Antihypertensive Drug class used | |||
| Ca-Antagonists | 23 | ||
| ACE inhibitors | 29 | ||
| AT1 receptor inhibitors | 16 | ||
| Diuretics | 18 | ||
| β-Blockers | 12 | ||
| Patient therapy with drugs from |
1 class 32 2 classes 12 3 classes 10 4 classes 3 |
ETCO2: end-tidal carbon dioxide concentration.